OvaScience names Harald Stock president and CEO
Dr. Stock has served on the OvaScience Board of Directors since 2013 and brings extensive experience globally scaling operations and commercialization for innovative, emerging growth healthcare companies.
Most recently, Dr. Stock served as President and CEO of Sweden-based ArjoHuntleigh, an acute and long-term care equipment company.
Dr. Stock also served as Executive Vice President, Extend Care Business Area, of Getinge Group, the publicly listed principal owner of ArjoHuntleigh.
Before joining ArjoHuntleigh and Getinge Group, Dr. Stock was the CEO of Grünenthal, an international research-based pharmaceutical company headquartered in Germany, where he led the global transformation to focus on innovative pain medications and expand in Latin America.
Prior to joining Grünenthal in 2009, Dr. Stock was Chairman and Managing Director at DePuy, the Orthopedics Division of Johnson & Johnson.
Previously, he led corporate divisions of the Roche Group including Senior Vice President of the Global Near Patient Testing business.
Dr. Stock holds a Ph.D. in Inorganic Chemistry from Ruprecht-Karls-University of Heidelberg, Germany.
He succeeds OvaScience Co-founder Michelle Dipp, M.D., Ph.D., who will now serve as Executive Chair of the Board of Directors.